 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton Universitys Department of Neuroscience, will make a presentation on the anti-depressant activity of the companys lead compound, its proprietary 2-bromo-LSD BETR-001, at the four-day American College of Neuropsychopharmacology ACNP annual conference in Phoenix, Arizona starting on December 4, 2022. The Vancouver, British Columbia-based biotechs BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide LSD derivative molecule. 